Ultragenyx Pharmaceuticals (RARE +3.9%) announces the dosing of the first patient in a Phase 2 clinical trial assessing Fast Track-designated recombinant human beta-glucuronidase (rhGUS) (UX003) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback